La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Sensei Biotherapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Sensei Biotherapeutics..

Sensei Biotherapeutics (NASDAQ:SNSE) Azioni, Catena delle Opzioni

Sensei Biotherapeutics

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) November Xbox Game Pass lineup offers a diverse selection, featuring everything from tactical RPGs to quirky simulators and <a href="https://www.benzinga.com/general/gaming">high-fidelity flight experiences.</a>
Here's what's coming to Game Pass this month, as <a href="https://news.xbox.com/en-us/2024/11/04/xbox-game-pass-november-2024-wave-1/">announced</a> in an Xbox Wire post:
<ul>
<li>Metal Slug Tactics (Cloud, Console, and PC – Nov. 5) Dive into this dynamic tactical RPG that combines the iconic run-and-gun action of the Metal Slug series with roguelite elements. Assemble your squad and conquer the battlefield in this strategic twist on a classic.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41694104/microsofts-decision-to-shut-down-arkane-austin-called-stupid-by-studio-founder">Microsoft&#8217;s Decision To Shut Down Arkane Austin Called &#8216;Stupid&#8217; By Studio Founder</a>
<ul>
<li>StarCraft: Remastered (PC – Nov. 5) Experience the legendary sci-fi real-time strategy game that set the bar for the genre. With enhanced graphics, relive the battles between the Terran, Protoss, and Zerg in this definitive version of the original StarCraft.</li>
<li>StarCraft II: Campaign Collection (PC – Nov. 5) Delve into the epic campaigns of StarCraft II, featuring immersive single-player stories and intense strategy gameplay. This collection brings together the entire StarCraft II narrative, perfect for fans and newcomers alike.</li>
<li>Go Mecha Ball (Console – Nov. 6) Engage in fast-paced, mecha-themed action as you control a ball-shaped robot on a mission. This title combines unique mechanics and challenging levels, offering a fresh take on robot combat.</li>
<li>Harold Halibut (Xbox Series X&#x7C;S – Nov. 6) Step into an underwater world crafted with stop-motion aesthetics in this narrative-driven adventure. Follow Harold, a lab assistant on a spaceship submerged in an ocean, as he unravels a heartfelt story.</li>
<li>The Rewinder (Console – Nov. 6) Inspired by Chinese folklore, this puzzle-adventure game follows the journey of a Rewinder who can manipulate memories. Help lost souls resolve their regrets in a mystical, hand-drawn world.</li>
<li>Turnip Boy Robs a Bank (Console – Nov. 6) Take control of the mischievous Turnip Boy in this quirky action-adventure, where he teams up with a mob of veggies to rob a bank. Expect humor, action, and plenty of surprises.</li>
<li>Goat Simulator Remastered (Cloud, PC, and Xbox Series X&#x7C;S – Nov. 7) The ultimate chaos simulator returns with upgraded graphics and classic DLCs. Headbutt, flip, and lick your way through a sandbox world in this redefined edition of the fan-favorite Goat Simulator.</li>
<li>Microsoft Flight Simulator 2024 (Cloud, PC, and Xbox Series X&#x7C;S – Nov. 19) Push your piloting skills to new heights in the latest installment of Microsoft Flight Simulator. Featuring a vast fleet of aircraft and the most realistic world map to date, this edition brings dynamically generated missions and the ultimate in simulation realism.</li>
</ul>
<h3 class="wp-block-heading">Games Leaving Game Pass On Nov. 15, 2024:</h3>
Be sure to wrap up your gameplay in the following titles before they leave the service:
<ul>
<li>Dicey Dungeons (Cloud, Console, and PC)</li>
<li>Dungeons 4 (Cloud, Console, and PC)</li>
<li>Goat Simulator (PC)</li>
<li>Like a Dragon: Ishin! (Cloud, Console, and PC)</li>
<li>Like a Dragon: The Man Who Erased His Name (Cloud, Console, and PC)</li>
<li>Persona 5 Tactica (Cloud, Console, and PC)</li>
<li>Somerville (Cloud, Console, and PC)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/10/41633013/sony-adds-new-death-note-game-to-november-ps-plus">Sony Adds New Death Note Game To November PS Plus</a></li>
</ul>
Image credits: Shutterstock.

Gaming

News

General

MSFT

Xbox Game Pass November: Metal Slug Tactics, Flight Simulator Lead New Releases

WIIM

XMTR

Xometry shares are trading higher after the company reported better-than-expected Q3 financial results.

RBC Capital analyst Daniel Perlin maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Outperform and raises the price target from $95 to $104.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Fidelity National Info, Raises Price Target to $104

As Election Day 2024 unfolds, <a href="https://www.benzinga.com/topic/massachusetts">Massachusetts</a> and <a href="https://www.benzinga.com/topic/oregon">Oregon</a> are capturing national attention with pivotal ballot measures on psychedelics. Both states have the potential to reshape U.S. mental health treatment by advancing policies on substances like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/mdma">MDMA</a>, part of the &#8220;psychedelic renaissance&#8221; in mental health care. These efforts signify growing momentum behind <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapy</a> as a solution for PTSD, depression, and addiction, aiming to address urgent mental health needs.
<h3 class="wp-block-heading">Massachusetts' Question 4: Legalization And Regulation Of Psychedelics</h3>
Massachusetts voters face an important decision with Question 4, which would legalize and decriminalize psychedelics for therapeutic and personal use. If passed, it would allow licensed providers to administer substances like psilocybin and MDMA for therapy and decriminalize personal use and home cultivation of psilocybin.
This initiative marks Massachusetts&#8217; first state-level push for psychedelic reform, potentially setting a precedent for other states. However, the campaign has encountered internal disagreements, particularly around the measure's dual focus on therapeutic legalization and personal decriminalization, stirring debates on potential risks like unregulated recreational use.
<h3 class="wp-block-heading">Key Supporters And Opposition In Massachusetts</h3>
The campaign for Question 4 is backed by strong support from veterans groups and drug policy advocates. The Heroic Hearts Project, a veterans&#8217; service organization has been especially vocal. The group is promoting the measure as a critical alternative treatment for veterans suffering from PTSD and other mental health conditions. Massachusetts for Mental Health Options, the primary group <a href="https://www.benzinga.com/markets/cannabis/24/10/41320243/massachusetts-veterans-advocate-for-psilocybin-legalization-will-voters-support-them">backing the measure</a>, has received endorsements from numerous veteran advocates, who see psychedelics as a promising path to healing when traditional treatments fail.
<h3 class="wp-block-heading">Local Support</h3>
Eight<a href="https://www.benzinga.com/markets/cannabis/24/02/37158739/medford-massachusets-move-to-decriminalize-psychedelics-has-statewide-reform-implications"> Massachusetts cities</a> including Salem, Somerville and Cambridge have adopted policies deprioritizing the enforcement of laws against psychedelics. Cambridge and Somerville city councils endorsed the statewide ballot measure, signaling growing momentum for change at the local level.
Despite growing support, the measure has faced opposition. A majority of Massachusetts&#8217; Special Joint Committee on Ballot Initiatives recommended against it in May, citing concerns over its broad scope. Governor Maura Healey introduced a veterans-focused bill to study psilocybin's therapeutic potential but expressed caution about full-scale legalization. Critics say the measure's decriminalization and legalization could lead to unintended consequences, like increased recreational use or regulatory challenges. The No campaign, backed by groups like Smart Approaches to Marijuana, has raised public health concerns, urging voters to reject it.
Polls indicate that Massachusetts' electorate remains divided, with undecided voters likely to influence the final outcome. Voter turnout and public interpretation of the initiative's complexities could ultimately determine its success.
<h3 class="wp-block-heading">Oregon's Evolving Psychedelic Landscape</h3>
In Oregon, where voters approved psilocybin therapy with Measure 109 in 2020, the state is once again at the forefront of psychedelic reform. Following its landmark <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">decriminalization of all drug possession</a> under Measure 110, Oregon is considering additional measures in 2024 to further expand access to psychedelic therapies, potentially addressing a wider array of mental health conditions and setting an example for other states.
These measures demonstrate Oregon's commitment to harm reduction and therapeutic options over punitive drug policies. For advocates nationwide, Oregon's ongoing initiatives offer a potential model for expanding regulated psychedelic therapy and decriminalization.
<h3 class="wp-block-heading">Federal Influence And Psychedelic Reform Movement</h3>
As <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">state initiatives gain momentum</a>, federal policy on psychedelics remains uncertain. While the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a> has approved limited research, broader legalization and therapeutic use are still unclear. However, bipartisan support for psychedelic research is growing. With votes on Massachusetts&#8217; Question 4 and Oregon&#8217;s initiatives, 2024 could be a pivotal year, particularly for MA, which may set a precedent for expanding access to transformative mental health therapies.
Cover image made with AI

Cannabis

Government

Psychedelics

Politics

Legal

2024 Election Spotlight: Massachusetts And Oregon Tackle Psychedelics Reform

Shares of MasTec Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) continued their upward trajectory in early trading on Tuesday, after climbing last week on <a href="https://www.benzinga.com/news/24/11/41688665/amazon-posts-upbeat-results-joins-cardinal-health-waters-atlassian-charter-communications-mastec-and">the company's raised 2024 adjusted earnings guidance</a>.
Despite the recent rally, the stock has more runway. The Coral Gables, Florida-based company's Power Delivery, Clean Energy &amp; Infrastructure (CE&amp;I), and Communications segments are "turning the corner," according to Truist Securities.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af1b85e930001e6383a/jamie-cook">Analyst Jamie Cook</a> upgraded the rating for MasTec from Hold to Buy, while raising the price target from $133 to $173.
The MasTec Thesis: The company's Power Delivery, CE&amp;I, and Communications segments are poised for revenue growth and margin expansion, Cook said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
MasTec is "solidifying its positioning in utility transmission and distribution through the Henkels &amp; McCoy acquisition and in renewables through the IEA acquisition," the analyst stated. 
The company and rival Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) are both "well positioned to lead the market and grow given competitive advantages which include scale, workforce, and balance sheet," he added.
"We expect strong top line growth and margin expansion in 2025 tied to secular growth in renewables, significant funding for communications infrastructure associated with BEAD funding and MTZ's recently expanded relationship with AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), and new major project wins including the $1.5 billion high-voltage transmission project MTZ announced last quarter," Cook wrote. After facing two years of margin pressure, MasTec seems poised for margin expansion in 2025 and "has line of sight to reaching double-digit EBITDA margins over the medium term," he further said.
Price Action: Shares of MasTechad risen by 3.22% to $136.87 at the time of publication on Tuesday.
Read More: <a href="https://www.benzinga.com/news/earnings/24/09/40859294/mastec-stock-rallies-31-in-the-past-6-months-is-mtz-a-buy-right-now">MasTec Stock Rallies 31% in the Past 6 Months: Is MTZ a Buy Right Now?</a>

Analyst Color

Long Ideas

Upgrades

Movers

Trading Ideas

Infrastructure Construction Company MasTec Is Poised For Double Digit Margin Expansion, Analyst Says

BOWL

Bowlero Corp shares are trading higher. JP Morgan maintained an Overweight rating on the stock.

Piper Sandler analyst Korinne Wolfmeyer reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Neutral and raises the price target from $18 to $21.

Reiteration

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Piper Sandler Reiterates Neutral on Hims & Hers Health, Raises Price Target to $21

HCKT

Hackett Group shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 adjusted EPS guidance above estimates. Also, Craig-Hallum raised its price target on the stock from $30 to $32.

In the current session, the stock is trading at $3.81, after a 3.81% increase. Over the past month, LexinFintech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) stock increased by 14.15%, and in the past year, by 80.20%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_0.png" alt="Past Year Chart" />

<h3>LexinFintech Holdings P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 24.2 in the Consumer Finance industry, LexinFintech Holdings Inc. has a lower P/E ratio of 5.3. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into LexinFintech Holdings Inc's Price Over Earnings

Piper Sandler analyst Thomas Champion reiterates Vimeo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) with a Neutral and raises the price target from $5 to $7.

VMEO

Piper Sandler Reiterates Neutral on Vimeo, Raises Price Target to $7

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 5.24% on an annualized basis producing an average annual return of 18.49%. Currently, NRG Energy has a market capitalization of $17.75 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $234.21 today based on a price of $86.00 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730824226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today

Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) has outperformed the market over the past 5 years by 16.86% on an annualized basis producing an average annual return of 30.12%. Currently, Datadog has a market capitalization of $42.19 billion. 
Buying $1000 In DDOG: If an investor had bought $1000 of DDOG stock 5 years ago, it would be worth $3,814.23 today based on a price of $125.14 for DDOG at the time of writing.
<h3>Datadog's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730824221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DDOG

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,800 Today

Clearwater Paper shares are trading higher. RBC Capital reiterated an Outperform rating on the stock.

ICHR

Ichor Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates. Also. B. Riley Securities raised its price target on the stock from $36 to $38.

INGR

Ingredion shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and raised its FY24 adjusted EPS guidance above estimates.

Piper Sandler analyst Adam Maeder reiterates Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and raises the price target from $255 to $260.

INSP

Piper Sandler Reiterates Overweight on Inspire Medical Systems, Raises Price Target to $260

RBC Capital analyst Conor McNamara maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and raises the price target from $86 to $89.

HOLX

RBC Capital Maintains Sector Perform on Hologic, Raises Price Target to $89

AOSL

Alpha & Omega shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. B. Riley Securities lowered its price target on the stock from $50 to $47.

Mark Cuban is an outspoken billionaire and part-owner of the Dallas Mavericks but also one of the most vocal critics of the former president. He has used terms like &#8220;fascist&#8221; to describe Trump&#8217;s behavior. However, Cuban was recently seen on ABC justifying his business relationship with Miriam Adelson, who gave Trump an astounding $100 million to support his 2024 election campaign.
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Adelson&#8217;s hefty donation to Trump – the largest of any sports team owner – shows she's all-in on Trump's campaign. That has made things somewhat awkward for Cuban, considering his loud and clear support for Kamala Harris, who is running against Trump.
Yet, when asked how he felt about this partnership, Cuban brushed off the issue. &#8220;Do you know how everyone is voting who you work with? Do you know how the owners of your company are voting? This is America. People get to choose their candidates and vote for who they want, which makes it amazing,&#8221; Cuban said in an interview. Cuban&#8217;s message is that differing political views shouldn't interfere with running a business.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
Cuban also pointed out that he's not giving money to Harris – or any other political candidate, for that matter. Despite his <a href="https://www.benzinga.com/news/24/09/40745014/kamala-harris-is-pro-business-mark-cuban-says-vice-presidents-centre-100-policies-differ-from-bidens">vocal support for the current vice president</a>, Cuban hasn&#8217;t donated a penny to her campaign. He believes in making a difference through his words and influence instead of writing checks.
He's been on social media defending Harris and has engaged in fiery debates, <a href="https://www.benzinga.com/markets/equities/24/10/41568486/mark-cuban-highlights-trumps-potential-to-ruin-christmas-but-he-might-also-end-up-spoiling-the-p">calling out Trump's behavior</a> as dangerous and out of touch. Cuban also stated in the same ABC interview that &#8220;Donald Trump is not a normal candidate,&#8221; claiming that he has used divisive language and taken actions that, in Cuban&#8217;s opinion, verge on authoritarianism.
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
Despite clashing ideologies, Cuban seems comfortable keeping his business relationships and political beliefs separate. Miriam Adelson, who inherited a vast fortune from her late husband Sheldon Adelson, now <a href="https://www.benzinga.com/news/23/12/36231225/mark-cuban-to-retain-25-stake-in-dallas-mavericks-after-sale-to-adelson-family-report">shares ownership of the Mavericks with Cuban</a>. The Adelson family is deeply involved in politics and their support of Trump hasn't wavered. On the other hand, Cuban is sticking to his guns – supporting Harris in the media and making the case for what he believes is best for the country.
At the end of the day, Cuban seems determined to stay true to his political convictions and his business partnerships. &#8220;This is America,&#8221; he says – a place where people can disagree, even sharply and still find ways to work together.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Startups

'This Is America,' Mark Cuban Says, Justifying His Business Relationship With Trump's $100M Megadonor And Mavericks Co-Owner

<a href="https://www.benzinga.com/personal-finance/24/09/40714364/survive-anything-kevin-oleary-claims-you-need-5-million-in-savings-heres-how-you-can-reach-that-">Kevin O'Leary</a>, best known from Shark Tank, has backed Elon Musk's sweeping $2 trillion plan to slash federal spending. With former President Donald Trump's backing, Musk is proposed to head the Department of Government Efficiency (DOGE) if Trump secures a second term.&nbsp;
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
O'Leary enthusiastically remarked on Fox News, "Release the hounds" about unleashing Musk's cost-cutting skills across federal agencies. "Let them in there and come back with a shopping list of ideas and let's debate it. Why not? We need to find some savings."
In O'Leary's view, the U.S. federal government is "the biggest business in America." He sees Musk, the mind behind Tesla and SpaceX, as uniquely equipped to tackle this budget behemoth.&nbsp;
"Who has the executional skills and the track record to even look at this problem?" he said, emphasizing that Musk's focus and determination make him an ideal candidate. Indeed, O'Leary believes that Musk's efficiency ethos, which has driven companies like SpaceX to success, would transfer seamlessly to federal budget cuts – an area few entrepreneurs would tread.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Musk has clarified that he views today's government spending as unsustainable, especially with national debt interest payments now outstripping the defense budget.&nbsp;
Speaking at a Trump rally, he linked federal spending to inflation and increased taxes, which he warned are squeezing <a href="https://www.benzinga.com/personal-finance/24/08/40582239/californias-new-plan-taxpayers-might-soon-be-funding-home-loans-for-illegal-migrants-heres-what-">taxpayers </a>dry. With his proposal to shave off $2 trillion, Musk aims to start the work he sees as vital for long-term economic stability.
But this grand vision has detractors. Some experts question whether cutting a third of federal spending is possible without compromising essential services.&nbsp;
Analysis from the Washington Post noted that Musk&#8217;s cuts could gut programs like health care, food security and housing, impacting millions of Americans. Even previously untouchable sectors, such as Social Security and the military, may be affected.&nbsp;
See Also: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Musk acknowledged on X (formerly Twitter) that his proposed cuts could result in economic turmoil, suggesting that hard times would be ahead before any benefits emerged.
Still, O'Leary remains undeterred. He sees Musk's focus as an asset, contrasting the entrepreneur's "100% signal" approach with what he describes as other business leaders' focus on "noise." To O'Leary, Musk's dedication to his projects means he is all about the mission and not distracted by side issues, making him ideal for leading such a challenging initiative.&nbsp;
He even suggested that Musk go beyond the $2 trillion target. "We've got to go find $2 trillion; we've got to go find $5 trillion," O'Leary urged.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

Kevin O'Leary Supports Elon Musk's $2 Trillion Plan To Slash Government Spending With Trump's Backing–'It's Time To Release The Hounds'

LIDR, HOOK and BCAB among mid-day movers

Sensei stock plunges 46% in wake of Phase 1 data

An update from Sensei Biotherapeutics (SNSE) is now available. Sensei Biotherapeutics, Inc. has refreshed its corporate presentation, revealing it ...

Sensei Biotherapeutics Unveils Updated Corporate Presentation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sensei Biotherapeutics (SNSE – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE) and Omeros (OMER)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sensei Biotherapeutics (SNSE – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Viking Therapeutics (VKTX)

Sensei Biotherapeutics (SNSE) has shared an announcement. Dr. Jessie English has announced her resignation from the Board of Directors at Sensei Bi...

Dr. Jessie English Resigns from Sensei Biotherapeutics Board

Sensei Biotherapeutics GAAP EPS of -$0.28

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) just reported results for the second quarter of 2024.<ul><li>Sensei Biotherapeutics reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/snse-stock-earnings-sensei-biotherapeutics-for-q2-of-2024/">SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024

Sensei Biotherapeutics (SNSE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward White ...

Buy Rating Affirmed for Sensei Biotherapeutics on Strong Financials and Promising Drug Trials

Sensei Biotherapeutics ( ($SNSE) ) just unveiled an announcement. Sensei Biotherapeutics, Inc. recently appointed Josiah Craver as their new princi...

Sensei Biotherapeutics Appoints New Financial Chief

AKAN

BCAB

GNLX

HOOK

ISSC

LICN

LIDR

LUCY

MRUS

NCPL

OKLO

OMER

ONMD

REGN

RNAZ

SMMT

SNSE

SWIN

TLSI

TROO

VKTX

VSTM

Press Releases

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Health Care

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Earnings

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Comments

Sensei Biotherapeutics

Sensei Biotherapeutics (SNSE) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO